Neurocrine Biosciences valuation
Valuation
The P/E ratio is 24.5. The average price target of 28 analysts is $208.54.
Data as of November 17, 2026
Neurocrine Biosciences compared with similar companies
Neurocrine Biosciences's P/E (trailing 12 months): 24.5, in line with the median of a group of 9 similar companies (24.5).
| Metric | Neurocrine Biosciences | Median | 25th–75th percentile | Band |
|---|---|---|---|---|
| P/E (trailing 12 months) | 24.5 | 24.5 | 19.3 – 59.4 | Middle |
| Forward P/E | 13.4 | 17.2 | 14.4 – 30.2 | Low |
| EV/EBITDA | 15.4 | 15.4 | 14.0 – 17.3 | Middle |
| Price/book | 4.32 | 5.27 | 3.71 – 10.1 | Middle |
| Price/sales | 4.52 | 4.39 | 3.06 – 7.18 | Middle |
| Gross margin | 64.7% | 73.8% | 64.7% – 80.8% | Low |
| Operating margin | 26.6% | 28.7% | 20.4% – 36.3% | Middle |
| Net margin | 19.0% | 19.9% | 12.2% – 34.3% | Middle |
| ROE | 20.4% | 16.0% | 13.6% – 20.1% | High |
| Debt/equity | 0.12 | 0.39 | 0.12 – 2.13 | Middle |
Group: the stock and up to 10 companies in the same industry (with fewer than 5, related industries too), same region first, with a similar size. Band: low = the lowest quarter of values in the group, middle = 25th to 75th percentile, high = the highest quarter. Negative multiples and multiples above 500 are excluded; a comparison needs at least 5 values. The group is recalculated nightly.
TickerLandia analysisHow it is calculated
Companies in the group: same industry, similar size
Neurocrine Biosciences: valuation over time
On the latest fiscal year's earnings (2025), Neurocrine Biosciences's P/E today is 35.4, below the median of its last 7 fiscal years (53.3; between 23.0 and 275.6 from 2019 to 2025). Relative to earnings, the stock costs less than it used to.
| Fiscal year | Price at year end | Earnings per share | P/E |
|---|---|---|---|
| 2025 | $141.83 | $4.67 | 30.4 |
| 2024 | $136.50 | $3.29 | 41.5 |
| 2023 | $131.76 | $2.47 | 53.3 |
| 2022 | $119.44 | $1.56 | 76.6 |
| 2021 | $85.17 | $0.92 | 92.6 |
| 2020 | $95.85 | $4.16 | 23.0 |
| 2019 | $107.49 | $0.39 | 275.6 |
| 2018 | $71.41 | $0.22 | — |
| 2017 | $77.59 | -$1.62 | — |
| 2016 | $38.70 | -$1.63 | — |
TickerLandia calculation: closing price on the last trading day of the fiscal year divided by diluted earnings per share from the annual report (positive earnings only). Prices adjusted for splits. Today's P/E is today's price divided by the latest fiscal year's earnings per share, so it compares with the years above.
TickerLandia analysisHow it is calculated
Other metrics
Valuation multiples
- Market cap
- $16.73B
- Enterprise value
- $16.45B
- PEG
- 0.33
- EV/revenue
- 4.44
Profitability and growth
- ROA
- 12.5%
- ROIC
- 20.2%
- Revenue growth (year over year)
- 41.2%
- Earnings growth (year over year)
- -3.9%
Financial health
- Total cash
- $737.9M
- Total debt
- $451.8M
- Current ratio
- 2.04
- Quick ratio
- 1.72
- Altman Z-Score
- 6.72
- Piotroski F-Score
- 6.00
Dividends
- Dividend yield
- 0.0%
- Payout ratio
- 0.0%
- Ex-dividend date
- December 29, 1995
Analysts and estimates
- Average price target
- $208.54
- Median price target
- $215.00
- High price target
- $253.00
- Low price target
- $150.00
- Analysts with a price target
- 28
- Consensus
- Strong buy
- Forward EPS
- $12.30
- EPS estimate, current year
- $10.59
Shares and trading
- Beta
- 0.33
- Average volume
- 1.31M
- Shares outstanding
- 101.22M
- Float
- 99.9M
- Institutional ownership
- 104.9%
- Insider ownership
- 1.1%
- Short interest (% of float)
- 7.6%
- Short ratio (days)
- 4.53
